FDA advisory committee backs Gilead’s Descovy for PrEP

An FDA advisory committee voted 16-2 recommending approval of Gilead Sciences’ (GILD -0.2%) Descovy (emtricitabine and tenofovir) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in men and transgender women who have sex with men.

The FDA’s action date is in October.

https://seekingalpha.com/news/3488717-fda-advisory-committee-backs-gileads-descovy-prep